GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Novacyt SA (XPAR:ALNOV) » Definitions » Debt-to-Equity

Novacyt (XPAR:ALNOV) Debt-to-Equity : 0.00 (As of Jun. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Novacyt Debt-to-Equity?

Novacyt's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.20 Mil. Novacyt's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.26 Mil. Novacyt's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €125.06 Mil. Novacyt's debt to equity for the quarter that ended in Jun. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Novacyt's Debt-to-Equity or its related term are showing as below:

During the past 12 years, the highest Debt-to-Equity Ratio of Novacyt was 0.75. The lowest was 0.00. And the median was 0.08.

XPAR:ALNOV's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.21
* Ranked among companies with meaningful Debt-to-Equity only.

Novacyt Debt-to-Equity Historical Data

The historical data trend for Novacyt's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novacyt Debt-to-Equity Chart

Novacyt Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.75 0.02 0.01 0.01

Novacyt Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.01 0.01 -

Competitive Comparison of Novacyt's Debt-to-Equity

For the Medical Devices subindustry, Novacyt's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novacyt's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Novacyt's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Novacyt's Debt-to-Equity falls into.



Novacyt Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Novacyt's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Novacyt's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novacyt  (XPAR:ALNOV) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Novacyt Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Novacyt's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Novacyt (XPAR:ALNOV) Business Description

Traded in Other Exchanges
Address
13, Avenue Morane Saulnier, Velizy-Villacoublay, FRA, 78140
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.

Novacyt (XPAR:ALNOV) Headlines

No Headlines